Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Clinical trial NCT02127970 · COMPLETED

Trial details

NCT number: NCT02127970
Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Abscess Wound Infection Surgical Site Infection Cellulitis

Start date: 2014-04-18
Primary completion: 2015-03-11
Enrollment: 698

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.